Clinical trials: Hot Flashes
Hot Flashes
A Study in Canada to Follow Outcomes of Women in Menopause Treated With Fezolinetant for Hot Flashes, When Given in Clinical Practice
This study is for women in Canada who are in menopause. They have symptoms including hot flashes and night sweats (also known as vasomotor symptoms or VMS).
- Trial name
- CANDLELIGHT (NCT07602530)
- Testing
- Fezolinetant
- Where
- 2 sites in Canada
- Volunteers
- 238 people
- Sponsor
- Astellas Pharma Europe Ltd.
Menopause, Hot Flashes
Study Evaluating DVS-233 SR to Treat Vasomotor Systems Associated With Menopause
The purpose of this study is to assess the safety and efficacy of desvenlafaxine succinate (DVS) for treatment of moderate to severe vasomotor symptoms (VMS) that are associated with menopause, and also to assess the effects of…
- Conditions
- Menopause, Hot Flashes, Sleep Disorders
- Trial name
- NCT00256685
- Testing
- DVS-233 SR
- Volunteers
- 568 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Hot Flashes
A Study in Germany to Learn About the Value of Fezolinetant in Treating Hot Flashes and Night Sweats in Women During Menopause
This study is for women in Germany who are going through menopause. They have symptoms including hot flashes and night sweats (also called vasomotor symptoms).
- Trial name
- GRACE (NCT07455812)
- Testing
- Fezolinetant
- Where
- Germany
- Volunteers
- 105 people
- Sponsor
- Astellas Pharma Europe Ltd.
PMS, Hot Flashes
A Study to Evaluate the Effects of RCN3028 on Moderate to Severe Vasomotor Symptoms in Women
Hot flashes are the most common symptom of menopause and affect almost 75% of menopausal women. Clinical evidence indicates potent antagonists of 5-HT2A are more likely to cause hypothermia.
- Trial name
- RDC (NCT02100540)
- Testing
- II RDC 0.3mg capsule, III RDC 0.6mg capsule
- Where
- Taiwan
- Volunteers
- 58 people
- Sponsor
- Yung Shin Pharm. Ind. Co., Ltd.
Fever, Sweats, and Hot Flashes, Infection
Recombinant Human Mannose-Binding Lectin (MBL) in Treating Young Patients With MBL Deficiency and Fever and Neutropenia
RATIONALE: Recombinant human mannose-binding lectin (MBL) may be effective in preventing infection in young patients with fever and neutropenia receiving chemotherapy for blood disease or cancer.
- Conditions
- Fever, Sweats, and Hot Flashes, Infection, Leukemia, Lymphoma
- Trial name
- NCT00886496
- Testing
- recombinant human mannose-binding lectin
- Where
- 3 sites in United States
- Sponsor
- Enzon Pharmaceuticals, Inc.